These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 22156347)
1. Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones. Uzana R; Eisenberg G; Sagi Y; Frankenburg S; Merims S; Amariglio N; Yefenof E; Peretz T; Machlenkin A; Lotem M J Immunol; 2012 Jan; 188(2):632-40. PubMed ID: 22156347 [TBL] [Abstract][Full Text] [Related]
2. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498 [TBL] [Abstract][Full Text] [Related]
3. Antigen-specific transfer of functional programmed death ligand 1 from human APCs onto CD8+ T cells via trogocytosis. Gary R; Voelkl S; Palmisano R; Ullrich E; Bosch JJ; Mackensen A J Immunol; 2012 Jan; 188(2):744-52. PubMed ID: 22174448 [TBL] [Abstract][Full Text] [Related]
4. Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. Dufour E; Carcelain G; Gaudin C; Flament C; Avril MF; Faure F J Immunol; 1997 Apr; 158(8):3787-95. PubMed ID: 9103444 [TBL] [Abstract][Full Text] [Related]
5. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. Clay TM; Custer MC; Sachs J; Hwu P; Rosenberg SA; Nishimura MI J Immunol; 1999 Jul; 163(1):507-13. PubMed ID: 10384155 [TBL] [Abstract][Full Text] [Related]
6. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements. Gervois N; Heuze F; Diez E; Jotereau F Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794 [TBL] [Abstract][Full Text] [Related]
7. Presentation of acquired peptide-MHC class II ligands by CD4+ regulatory T cells or helper cells differentially regulates antigen-specific CD4+ T cell response. Zhou G; Ding ZC; Fu J; Levitsky HI J Immunol; 2011 Feb; 186(4):2148-55. PubMed ID: 21242518 [TBL] [Abstract][Full Text] [Related]
8. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition. Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717 [TBL] [Abstract][Full Text] [Related]
9. Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. Maeurer MJ; Chan HW; Karbach J; Salter RD; Knuth A; Lotze MT; Storkus WJ Eur J Immunol; 1996 Nov; 26(11):2613-23. PubMed ID: 8921947 [TBL] [Abstract][Full Text] [Related]
10. Antigen specific and MHC nonrestricted cytotoxicity of T cell receptor alpha beta+ and gamma delta+ human T cell clones isolated in IL-4. Paliard X; Yssel H; Blanchard D; Waitz JA; deVries JE; Spits H J Immunol; 1989 Jul; 143(2):452-7. PubMed ID: 2472439 [TBL] [Abstract][Full Text] [Related]
11. Evidence for involvement of the gamma, delta T cell antigen receptor in cytotoxicity mediated by human alloantigen-specific T cell clones. Rivas A; Koide J; Cleary ML; Engleman EG J Immunol; 1989 Mar; 142(6):1840-6. PubMed ID: 2466078 [TBL] [Abstract][Full Text] [Related]
12. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro. Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction. Anichini A; Mazzocchi A; Fossati G; Parmiani G J Immunol; 1989 May; 142(10):3692-701. PubMed ID: 2469723 [TBL] [Abstract][Full Text] [Related]
14. Specificity, T cell receptor diversity and activation requirements of CD4+ and CD8+ clones derived from human melanoma-infiltrating lymphocytes. Pandolfino MC; Viret C; Gervois N; Guilloux Y; Davodeau F; Diez E; Jotereau F Eur J Immunol; 1992 Jul; 22(7):1795-802. PubMed ID: 1623924 [TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity and lymphokine production of T cell receptor (TCR)-alpha beta+ and TCR-gamma delta+ cytotoxic T lymphocyte (CTL) clones recognizing HLA-A2 and HLA-A2 mutants. Recognition of TCR-gamma delta+ CTL clones is affected by mutations at positions 152 and 156. Spits H; Paliard X; Engelhard VH; de Vries JE J Immunol; 1990 Jun; 144(11):4156-62. PubMed ID: 2111341 [TBL] [Abstract][Full Text] [Related]
17. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898 [TBL] [Abstract][Full Text] [Related]
18. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Godet Y; Desfrançois J; Vignard V; Schadendorf D; Khammari A; Dreno B; Jotereau F; Labarrière N Eur J Immunol; 2010 Jun; 40(6):1786-94. PubMed ID: 20217862 [TBL] [Abstract][Full Text] [Related]
19. Large and dissimilar repertoire of Melan-A/MART-1-specific CTL in metastatic lesions and blood of a melanoma patient. Mandruzzato S; Rossi E; Bernardi F; Tosello V; Macino B; Basso G; Chiarion-Sileni V; Rossi CR; Montesco C; Zanovello P J Immunol; 2002 Oct; 169(7):4017-24. PubMed ID: 12244204 [TBL] [Abstract][Full Text] [Related]
20. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. Itoh T; Storkus WJ; Gorelik E; Lotze MT J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]